Novartis Responsibilities Sample Clauses
The "Novartis Responsibilities" clause defines the specific obligations and duties that Novartis must fulfill under the agreement. This may include providing products, services, technical support, or information necessary for the collaboration or transaction, as well as ensuring compliance with applicable laws and regulations. By clearly outlining what Novartis is required to do, this clause helps allocate responsibilities, set expectations, and prevent misunderstandings between the parties.
Novartis Responsibilities. Subject to the terms and conditions of this Agreement, including Section 5.1.2 and Section 5.5: (i) Novartis shall have the sole right to Commercialize the Licensed Product in the Field in the Novartis Territory and the sole right and responsibility, at Novartis’s sole cost and expense, itself or with or through its Affiliates, Sublicensees, or other Third Parties, to (A) book all sales of the Licensed Product in the Novartis Territory as a Monotherapy and/or for use in any Combination Regimen, (B) subject to Section 5.2, develop and implement the brand and commercial strategy to be used for the Licensed Product in the Novartis Territory and (C) conduct all marketing, promotion and sales activities for the Licensed Product in the Novartis Territory and (ii) except for the conduct by or behalf of BeiGene, whether directly or through its Affiliates, licensees or contractors, of BeiGene Permitted Commercialization Activities, Medical Affairs Activities in relation to the BeiGene Ongoing Clinical Trials, any other Clinical Trial included as a BeiGene responsibility as part of the Initial Global Development Plan and Permitted Combinations that include a BeiGene Permitted Combination Product, and Third Party Permitted Commercialization Activities pursuant to this Agreement, BeiGene and its Affiliates shall not have any right to, and shall not, conduct any Commercialization of the Licensed Product in the Field in or in respect of the Novartis Territory.
Novartis Responsibilities. Novartis shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in III.E of the CIA and that all records furnished to the IRO are accurate and complete.
Novartis Responsibilities. 16.1 Novartis shall ensure that all Representatives who provide Services have received training in Healthcare Compliance meeting the requirements of the OIG Compliance Program Guidance for Pharmaceutical Manufacturers within the last twelve (12) months.
16.2 Novartis will coordinate a training program with Barrier regarding the Product VusionTM (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment.
16.3 Novartis will cause all Calls to be performed as provided for in this Agreement.
Novartis Responsibilities. Novartis shall with Due Diligence provide the following resources to CombiChem and conduct the following activities under the Research Program as more fully described in the Research Plan:
(a) Novartis shall provide CombiChem with funding for the Collaboration as set forth in Article 8, provide structural and biological data on Hit(s) and screening results for Collaboration Compounds to CombiChem with respect to the Collaboration necessary for CombiChem to perform its duties under this Agreement, and will assume scientific, financial and administrative responsibility for screening and biological support activities, compound development and regulatory filings in the Field under the terms set forth below. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
(b) During the Research Period, Novartis shall provide CombiChem as quickly as possible, usually within *** days, test results for Collaboration Compounds from the assays related to the respective Collaboration Hit(s).
(c) During the Exclusivity Period, Novartis shall screen all Collaboration Compounds for In Vivo Activity in the Field, shall quarterly report these screening results to CombiChem and shall further evaluate Active Compounds and endeavor to determine Development Compounds in the Field.
(d) At any time during the Collaboration, Novartis may apply chemistry effort to any Collaboration Compound, including synthesis.
(e) Following the *** of the Novartis Crop Protection Stage Plan through First Commercial Sale, Novartis shall provide CombiChem with an annual report summarizing Novartis's activities in developing Development Compounds.
(f) During the Research Period and in connection with CombiChem providing the services in Section 2.1(c) above, Novartis shall send one (1) research chemist to conduct Novartis' activities at CombiChem's facilities under the Research Program. Novartis shall have sole responsibility for the expenses associated with its visiting chemist, including, without limitation, salary, travel, living and other associated expenses. CombiChem shall not charge any infrastructure costs for such chemist.